The findings of the study, which are consistent with other systematic reviews and meta-analyses, suggest that type 2 diabetes patients may benefit from a combination of pharmaceutical changes—such as GLP-1—dietary changes, and lifestyle changes to lower their risk of hypoglycemia during the fasting month of Ramadan. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.